HOME >> BIOLOGY >> NEWS
Discovering what genes do the high-throughput way

by the screen to characterize the effects of the RNAi treatment on the cells. They created a formal set of criteria to judge the cells consisting of seven classes of change that could have been induced. These included changes to cell number, shape, size and viability. Any changes were only considered significant if both scientists recorded them in replica experiments.

The researchers were also keen to find out if their method could be used to screen for genes that worked in, or inhibited specific molecular pathways. Screens in whole flies for genes that modify the effect of a particular genetic mutation have proved powerful, though time consuming. By adding two sets of double stranded RNA to each well, one that targeted the tumor suppressor gene pten and the other the gene to be tested, the researchers found that they were able to identify genes that modified the effects of inhibiting pten in cells. "These results demonstrate that modifier screens, as previously done in vivo, can be extended to RNAi screening methodology in cell culture", write the researchers.

Drug companies are becoming interested in this technique, as the rate-limiting step in cell-based drug discovery is finding out which protein is inhibited by a particular drug. Using Perrimon's method they can screen to see which gene, when inhibited, changes the cell in the same way as adding the drug.

"RNAi screens can complement classical Drosophila genetics to assign functions to both known and novel genes," write the researchers. "The same technology can be easily adapted to a wide variety of cell-based studies and a greater genomic scale."

Baum says, "The major difference between this and whole fly screens is that here we can be systematic. We can choose to look at any cell biological process and systematically test the set of genes that could be involved. In the future we will be able to screen the full genome in a few weeks, and look at any cell biological phenomenon.
'"/>

Contact: Gemma Bradley
press@biomedcentral.com
44-207-323-0323
BioMed Central
30-Sep-2003


Page: 1 2 3

Related biology news :

1. Discovering new regulators of the immune system
2. Discovering the Tree of Life
3. Discovering Virology From Beijerinck To Hyperlinks
4. "Discovering Biological Diversity" Is AAAS Topic For USGS Manager
5. Belgian researchers explore revolutionary approach to angiogenesis
6. Tracing genes, biologists show lizard migration is traced to Florida
7. Certain genes boost fish oils protection against breast cancer
8. Fossil genes reveal how life sheds form and function
9. Missing genes may help explain why plague bacteria are so deadly
10. Do genes respond to global warming?
11. Genetic map of important tree genes outlined

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Discovering what genes the high throughput way

(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) ... report "Neuroprotection - Drugs, Markets and Companies" ... describes the role of neuroprotection in acute disorders ... system as well as in chronic diseases such ... mechanisms of damage to neural tissues are similar ...
(Date:5/28/2015)... Texas (PRWEB) May 28, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... attending the World Pork Expo, June 3-5 in ... this year in a Wall Street Journal article ...
(Date:5/28/2015)... MIAMI BEACH, Fla. , May 28, 2015 /PRNewswire/ ... data supporting the anti-cancer potential of its growth hormone-releasing ... presentation at the 2015 ASCO Annual Meeting. The ... the target for Biscayne,s anti-cancer GHRH blockers, is present ... receptor status. These findings suggest that GHRH antagonists could ...
Breaking Biology Technology:Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
Cached News: